GENEVA (Reuters) – The World Health Organization said on Friday it had added its first monoclonal antibody tocilizumab to its so-called pre-qualification list, an official list of medicines used as a benchmark for procurement by developing countries.
The WHO recommended the drug, manufactured by Roche and typically used to treat arthritis, only for patients diagnosed with severe or critical COVID-19.
(Reporting by Emma Farge)
